Aguirre AJ, Hahn WC. Synthetic Lethal Vulnerabilities in -Mutant Cancers. Cold Spring Harb Perspect Med. 2018;8(8). doi:10.1101/cshperspect.a031518.

Niepel M, Hafner M, Duan Q, et al. Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. Nat Commun. 2017;8(1):1186. doi:10.1038/s41467-017-01383-w.

Zdraljevic S, Strand C, Seidel HS, Cook DE, Doench JG, Andersen EC. Natural variation in a single amino acid substitution underlies physiological responses to topoisomerase II poisons. PLoS Genet. 2017;13(7):e1006891. doi:10.1371/journal.pgen.1006891.

Hayes TK, Luo F, Cohen O, et al. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. Cancer Res. 2019;79(9):2352-2366. doi:10.1158/0008-5472.CAN-18-2711.

Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500-4. doi:10.1038/nature11183.

Almendro V, Cheng Y-K, Randles A, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014;6(3):514-27. doi:10.1016/j.celrep.2013.12.041.

Martz CA, Ottina KA, Singleton KR, et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014;7(357):ra121. doi:10.1126/scisignal.aaa1877.

Renfro LA, Mallick H, An M-W, Sargent DJ, Mandrekar SJ. Clinical trial designs incorporating predictive biomarkers. Cancer Treat Rev. 2016;43:74-82. doi:10.1016/j.ctrv.2015.12.008.

Birsoy K, Sabatini DM, Possemato R. Untuning the tumor metabolic machine: Targeting cancer metabolism: a bedside lesson. Nat Med. 2012;18(7):1022-3. doi:10.1038/nm.2870.

Berger AH, Imielinski M, Duke F, et al. Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene. 2014;33(35):4418-23. doi:10.1038/onc.2013.581.